FORT WORTH, Texas — Galderma Laboratories has rolled out a new nozzle for Clobex Spray, a super-potent topical steroid for moderate to severe plaque psoriasis.
The company said Tuesday that the new packaging for Clobex Spray (clobetasol propionate 0.05%), which will be on pharmacy shelves nationwide starting later this month, sports a more-targeted nozzle delivery system to help psoriasis patients apply the product more easily and precisely to affected areas of the body and scalp.
Clobex Spray comes in easy-to-use 2-ounce and 4.25-ounce bottles with a non-aerosol, measured-dose spray, and provides clinically proven relief of common symptoms associated with psoriasis, according to Galderma.
The efficacy of Clobex Spray was established in two independent clinical trials with 240 patients. On average, eight out of 10 patients with moderate to severe plaque psoriasis became clear or almost clear after four weeks of treatment, and the efficacy of Clobex Spray to treat moderate to severe plaque psoriasis has been confirmed in various clinical studies since its approval, the company said.
"Successful treatment of plaque psoriasis with topical steroids hinges upon a patient’s ability to regularly and accurately apply the medication to localized lesions," Dr. Fran Cook-Bolden, director of the Skin Specialty Group and assistant clinical professor of dermatology at Columbia University in New York, said in a statement released by Galderma. "Clobex Spray is already a trusted, easy-to-use treatment option for psoriasis. I think the new nozzle will enhance the patient’s experience with this medication by making the application process simpler and more targeted, and will give patients the Clobex efficacy they’ve come to trust while limiting potential medication overuse."